Overview

Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
0
Participant gender:
All
Summary
The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Penicillanic Acid
Piperacillin
Piperacillin, Tazobactam Drug Combination
Tazobactam
Criteria
Inclusion Criteria:

- Hospitalized patients over 16 years of age with complicated urinary infection produced
by bacteria that are suspected to be susceptible to treatment with
Piperacillin-tazobactam.

Exclusion Criteria:

- Patients known, or thought to be hypersensitivity to beta-lactams

- Patients with an uncomplicated urinary tract infection